Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

NCT02143648 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

373

Enrollment

INDUSTRY

Sponsor class

Conditions

Uremic Pruritus
Pruritus

Interventions

DRUG: nalbuphine HCl ER tablets 60 mg BID
DRUG: nalbuphine HCl ER tablets 120mg BID
DRUG: Placebo tablets BID

Sponsor

Trevi Therapeutics